Literature DB >> 11313155

D(2) and 5HT(2A) receptor occupancy of different doses of quetiapine in schizophrenia: a PET study.

O Gefvert1, T Lundberg, I M Wieselgren, M Bergström, B Långström, F Wiesel, L Lindström.   

Abstract

OBJECTIVE: Quetiapine is a novel antipsychotic agent with many atypical features, including low D(2) and higher 5HT(2A) affinity in vitro, low propensity to induce extra-pyramidal side effects and minimal effects on prolactin levels. The purpose of this study was to investigate, using positron emission tomography (PET), the relationship between plasma concentrations of different doses of quetiapine and occupancy of D(2) and 5HT(2A) receptors in schizophrenic patients.
METHODS: Five patients were treated with quetiapine (titrated to 750 or 450 mg/day) for 28 days, subsequently reduced weekly in a descending-dose schedule. Dopamine D(2) and 5HT(2A) occupancies were determined using [(11)C] raclopride and [(11)C] N-methylspiperone as ligands, respectively, and PET imaging.
RESULTS: Mean D(2) receptor occupancies of 41 and 30% were observed at quetiapine doses of 750 and 450 mg/day. At lower dose levels no occupancy could be determined. Quetiapine induced a consistently higher degree of 5HT(2A) receptor occupancy, with mean occupancies of 74 and 57% at doses of 750 and 450 mg/day, respectively. No EPS emerged during the trial and most of the pre-trial EPS resolved during the study.
CONCLUSIONS: In clinically effective doses, quetiapine induced low occupancy at D(2) receptors, which is consistent with atypical antipsychotics such as clozapine, and probably explains the lack of EPS observed in this trial. Correlations between receptor occupancy and plasma concentrations of quetiapine could not be calculated, although receptor occupancy increased with higher plasma concentrations for the 450 and 750 mg doses.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11313155     DOI: 10.1016/s0924-977x(00)00133-4

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  29 in total

Review 1.  Drug-induced sleep: theoretical and practical considerations.

Authors:  Jeffrey M Ellenbogen; Edward F Pace-Schott
Journal:  Pflugers Arch       Date:  2011-09-28       Impact factor: 3.657

2.  Dopamine D2 occupancy as a biomarker for antipsychotics: quantifying the relationship with efficacy and extrapyramidal symptoms.

Authors:  Rik de Greef; Alan Maloney; Per Olsson-Gisleskog; Joep Schoemaker; John Panagides
Journal:  AAPS J       Date:  2010-12-24       Impact factor: 4.009

Review 3.  Computational models of neuronal biophysics and the characterization of potential neuropharmacological targets.

Authors:  Michele Ferrante; Kim T Blackwell; Michele Migliore; Giorgio A Ascoli
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

4.  Neural correlates of the popular music phenomenon: evidence from functional MRI and PET imaging.

Authors:  Qiaozhen Chen; Ying Zhang; Haifeng Hou; Fenglei Du; Shuang Wu; Lin Chen; Yehua Shen; Fangfang Chao; June-Key Chung; Hong Zhang; Mei Tian
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-01-12       Impact factor: 9.236

Review 5.  Clinical Pharmacokinetics of Atypical Antipsychotics: An Update.

Authors:  Massimo Carlo Mauri; Silvia Paletta; Chiara Di Pace; Alessandra Reggiori; Giovanna Cirnigliaro; Isabel Valli; Alfredo Carlo Altamura
Journal:  Clin Pharmacokinet       Date:  2018-12       Impact factor: 6.447

6.  Histamine H1 receptor occupancy by the new-generation antipsychotics olanzapine and quetiapine: a positron emission tomography study in healthy volunteers.

Authors:  Hirotoshi Sato; Chihiro Ito; Kotaro Hiraoka; Manabu Tashiro; Katsuhiko Shibuya; Yoshihito Funaki; Takeo Yoshikawa; Ren Iwata; Hiroo Matsuoka; Kazuhiko Yanai
Journal:  Psychopharmacology (Berl)       Date:  2015-07-07       Impact factor: 4.530

7.  Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: Part II.

Authors:  R Miller
Journal:  Curr Neuropharmacol       Date:  2009-12       Impact factor: 7.363

Review 8.  Quetiapine: a review of its use in the treatment of bipolar depression.

Authors:  Gillian M Keating; Dean M Robinson
Journal:  Drugs       Date:  2007       Impact factor: 9.546

9.  A cross-validation study on the relationship between central D2 receptor occupancy and serum perphenazine concentration.

Authors:  Mirjam Talvik; Anna-Lena Nordström; Niels-Erik Larsen; Aurelija Jucaite; Simon Cervenka; Christer Halldin; Lars Farde
Journal:  Psychopharmacology (Berl)       Date:  2004-03-06       Impact factor: 4.530

Review 10.  Quetiapine: dose-response relationship in schizophrenia.

Authors:  Anna Sparshatt; Sarah Jones; David Taylor
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.